Zhou Hong

Dr. Zhou Hong

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2026 in Molecules
Verified
Journal Article
Open access
PDF file
YZYuanyuan Zhang
Yuanyuan Zhang
ZHZhou Hong
Zhou Hong
XJXiwei Jia
Xiwei Jia
MZMeimei Zhang
Meimei Zhang
HYHao Yang
Hao Yang
LZLishuang Zhou
Lishuang Zhou
An acidic heteropolysaccharide, named LCP-90-3, with a relative molecular weight of 14.02 kDa, was isolated and purified from the traditional heat-clearing Chinese medicine, Lysimachia christinae Hance. The monosaccharide residue analysis indicated that LCP-90-3 was composed of glucuronic acid, mannose, and arabinose in a molar ratio of 79.2: 3.6: 17.2. Linkage analysis further indicated that LCP-90-3 was mainly composed of 1,4-GlcpA, 1,4,6-GlcpA, 1,2-Araf, T-Manp, 1,3-Araf, and 1,4-Manp residues. Furthermore, LCP-90-3 demonstrated potent anti-inflammatory activity by significantly inhibiting the secretion of nitric oxide (NO), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in lipopolysaccharide (LPS)-treated ANA-1 cells. Interestingly, oral administration of LCP-90-3 at doses of 20, 40, and 80 mg/kg effectively mitigated LPS-induced acute liver injury in vivo by suppressing the overexpression of inflammatory mediators (NO, TNF-α, and IL-6), aminotransferases (ALT and AST) in serum, and markers of antioxidant capacity (MDA, CAT, and SOD) in the liver. Overall, these findings highlight LCP-90-3 as a novel leading polysaccharide for new drug candidate development against liver injury through modulation of inflammatory responses and oxidative stress.